Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy CNS Pharmaceuticals stock | $1.41

Learn how to easily invest in CNS Pharmaceuticals stock.

CNS Pharmaceuticals Inc is a biotechnology business based in the US. CNS Pharmaceuticals shares (CNSP) are listed on the NASDAQ and all prices are listed in US Dollars. CNS Pharmaceuticals employs 3 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in CNS Pharmaceuticals

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – CNSP – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

CNS Pharmaceuticals stock price (NASDAQ: CNSP)

Use our graph to track the performance of CNSP stocks over time.

CNS Pharmaceuticals shares at a glance

Information last updated 2021-10-23.
Latest market close$1.41
52-week range$1.38 - $4.46
50-day moving average $1.50
200-day moving average $1.78
Wall St. target price$6.25
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.60

Buy CNS Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
$20 per year
Financial advice powered by relationships, not commissions.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy CNS Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

CNS Pharmaceuticals price performance over time

Historical closes compared with the close of $1.41 from 2021-10-22

1 week (2021-10-13) -8.44%
1 month (2021-09-20) N/A
3 months (2021-07-23) -20.79%
6 months (2021-04-23) -31.22%
1 year (2020-10-23) -25.00%
2 years (2019-10-20) N/A
3 years (2018-10-20) N/A
5 years (2016-10-20) N/A

CNS Pharmaceuticals financials

Gross profit TTM $0
Return on assets TTM -85.28%
Return on equity TTM -154.26%
Profit margin 0%
Book value $0.45
Market capitalisation $38.7 million

TTM: trailing 12 months

Shorting CNS Pharmaceuticals shares

There are currently 372,977 CNS Pharmaceuticals shares held short by investors – that's known as CNS Pharmaceuticals's "short interest". This figure is 16.9% down from 448,709 last month.

There are a few different ways that this level of interest in shorting CNS Pharmaceuticals shares can be evaluated.

CNS Pharmaceuticals's "short interest ratio" (SIR)

CNS Pharmaceuticals's "short interest ratio" (SIR) is the quantity of CNS Pharmaceuticals shares currently shorted divided by the average quantity of CNS Pharmaceuticals shares traded daily (recently around 152235.51020408). CNS Pharmaceuticals's SIR currently stands at 2.45. In other words for every 100,000 CNS Pharmaceuticals shares traded daily on the market, roughly 2450 shares are currently held short.

However CNS Pharmaceuticals's short interest can also be evaluated against the total number of CNS Pharmaceuticals shares, or, against the total number of tradable CNS Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case CNS Pharmaceuticals's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 CNS Pharmaceuticals shares in existence, roughly 10 shares are currently held short) or 0.0218% of the tradable shares (for every 100,000 tradable CNS Pharmaceuticals shares, roughly 22 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against CNS Pharmaceuticals.

Find out more about how you can short CNS Pharmaceuticals stock.

CNS Pharmaceuticals share dividends

We're not expecting CNS Pharmaceuticals to pay a dividend over the next 12 months.

CNS Pharmaceuticals overview

CNS Pharmaceuticals, Inc. , a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M. D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc.

Frequently asked questions

What percentage of CNS Pharmaceuticals is owned by insiders or institutions?
Currently 37.748% of CNS Pharmaceuticals shares are held by insiders and 4.898% by institutions.
How many people work for CNS Pharmaceuticals?
Latest data suggests 3 work at CNS Pharmaceuticals.
When does the fiscal year end for CNS Pharmaceuticals?
CNS Pharmaceuticals's fiscal year ends in December.
Where is CNS Pharmaceuticals based?
CNS Pharmaceuticals's address is: 2100 West Loop South, Houston, TX, United States, 77027
What is CNS Pharmaceuticals's ISIN number?
CNS Pharmaceuticals's international securities identification number is: US18978H1023
What is CNS Pharmaceuticals's CUSIP number?
CNS Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 155184104

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site